Thoracic trauma
Conditions
Interventions
Trade Name: DEXDOR
Product Name: DEXDOR
Pharmaceutical Form: Concentrate for solution for infusion
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: In
Sponsors
University Hospital Grenoble
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Patient hospitalized in intensive care or USC • Patient with a closed chest trauma not intubated (TTS score> 6) • Patient row to social security • Major Patient Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 16 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 4
Exclusion criteria
Exclusion criteria: • EVA Rest> 3 • Agitation with RASS> 2 • Patient on DEX or treated with an alpha 2 agonist in the last 8 hours • Patients on home VNI (except for VS-PPC OSA) • analgesia by epidural catheter • Long-term treatment with neuroleptics • Contraindications to the VNI • Contraindications to the DEX
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Compare the length of the sessions of VNI under DEX and placebo in the thoracic trauma patient;Secondary Objective: 1) To compare the safety of the patient during the session of VNI in DEX through hetero assessment scales (RASS) and self-assessment (EVA dyspnea, pain EVA, analgesic consumption during the sessions). 2) Compare the effectiveness of the VNI on arterial blood gases according to sedation 3) Evaluate the safety: a collection of the number of adverse events attributable to DEX at meetings.;Primary end point(s): Duration of VNI sessions with and without DEX (minutes) | — |
Countries
France
Contacts
Public ContactDr TROUVE-BUISSON
University Hospital Grenoble
Outcome results
None listed